Convention All Academic Convention is the premier solution for your association's abstract management solutions needs. Submission - Custom fields, multiple submission types, tracks, audio visual, multiple upload formats, automatic conversion to pdf. Review - Peer Review, Bulk reviewer assignment, bulk emails, ranking, z-score statistics, and multiple worksheets! Reports - Many standard and custom reports generated while you wait. Print programs with participant indexes, event grids, and more! Scheduling - Flexible and convenient grid scheduling within rooms and buildings. Conflict checking and advanced filtering. Communication - Bulk email tools to help your administrators send reminders and responses. Use form letters, a message center, and much more! Management - Search tools, duplicate people management, editing tools, submission transfers, many tools to manage a variety of conference management headaches! Click here for more information.
Association: Name: ISA's 49th ANNUAL CONVENTION, BRIDGING MULTIPLE DIVIDES URL: http://www.isanet.org
Citation: URL: http://www.allacademic.com/meta/p251129_index.html Direct Link: HTML Code:

Blackwood, Elizabeth. and Brown, Sherri. "Health Governance and Pharmaceutical Product Development: Dilemmas in Exporting Clinical Research to Developing Countries" Paper presented at the annual meeting of the ISA's 49th ANNUAL CONVENTION, BRIDGING MULTIPLE DIVIDES, Hilton San Francisco, SAN FRANCISCO, CA, USA, Mar 26, 2008 <Not Available>. 2009-05-23 <http://www.allacademic.com/meta/p251129_index.html>

Blackwood, E. P. and Brown, S. A. , 2008-03-26 "Health Governance and Pharmaceutical Product Development: Dilemmas in Exporting Clinical Research to Developing Countries" Paper presented at the annual meeting of the ISA's 49th ANNUAL CONVENTION, BRIDGING MULTIPLE DIVIDES, Hilton San Francisco, SAN FRANCISCO, CA, USA Online <PDF>. 2009-05-23 from http://www.allacademic.com/meta/p251129_index.html

Publication Type: Conference Paper/Unpublished Manuscript Abstract: Pharmaceutical product development and distribution is a costly and protracted process. The problem of drug access is particularly acute in developing countries where prohibitive costs delay or prevent universal access to essential medicines. The effect has been a disproportionate disease burden in countries that can ill-afford to treat entirely preventable diseases. As pharmaceutical companies increasingly export their clinical research trials to developing countries questions arise concerning the level of access such practices provide companies to subject populations. This is a particularly important issue given that evidence suggests that the ethical standards of such research are not as high as that conducted in Western countries, and that participants are more willing to participate in clinical trials than their western counterparts, due largely to illness and poverty and inferior access to treatment. Employing case studies and qualitative interview data, this paper will explore these issues, arguing that important national and global health governance and corporate regulatory issues must be addressed in order to thwart the development of a neo/post-colonial model of pharmaceutical product development.

From Westphalianism to Global Governance: The G8, International Law, and Global Health Governance Through Public-Private Partnerships (PPPs)

Between Drug Patents and Public Health: Values, Global Governance and Institutional Framework in International Political Economy